BACKGROUND: Elderly Americans are at increased risk of head trauma, particularly fall related. The effect of warfarin on head trauma outcomes remains controversial.
Over 2 million Americans, many of them elderly, are started on warfarin annually, for various indications. 1 The rapid aging of the American population suggests that the number of chronically anticoagulated elderly patients will continue to grow in the coming years. 2 Older individuals are at unique risk of injury because of age-related deconditioning that predisposes them to injury, particularly because of falls. 3 Furthermore, frailty and comorbidities predispose older patients to worse outcomes after injury compared with younger patients. 4 Warfarin use at the time of injury may exacerbate outcomes, in particular after head injury where there is a risk of catastrophic intracranial hemorrhage (ICH). 5 Multiple studies have examined the effect of warfarin on outcomes after head injury. While some have shown that warfarin increases the risk of mortality, [5] [6] [7] [8] [9] others have found equivalent outcomes for warfarin users compared with patients who are not on warfarin [10] [11] [12] However, the majority of these studies have been single center or locoregional studies and have focused on ICH alone. To date, there is little national data on the impact of warfarin on the incidence of ICH after head injury and associated outcomes despite widespread use of warfarin in the growing US elderly population. Additionally, existing studies have struggled to correctly identify warfarin users, something that is often not accurately recorded in inpatient records.
Therefore, we used prescription drug claims of elderly beneficiaries who were on warfarin in the weeks before sustaining head injury. We sought to determine the effect of preinjury warfarin use on postinjury outcomes. We hypothesized that warfarin use at the time of injury would increase the incidence of ICH and result in more adverse outcomes including hospital admission, intensive care unit (ICU) care, and 30-day in-hospital mortality.
Methods
Data source and subject selection Medicare Provider and Analysis Review was used to obtain variables related to initial presentation after head injury and subsequent hospitalization including diagnoses (up to 10), procedures (up to 10), need for ICU care, hospital length of stay (LOS), ICU-LOS, and to calculate each patient's Elixhauser comorbidity index. 13 Similarly, outpatient claims files were used to determine patient diagnoses (up to 20) and Elixhauser index for patients who were treated and released after visits to the emergency room after head injury. Demographic factors (age, race, sex) were obtained from Medicare denominator files. Part D claims were used to obtain medication name, strength, date of prescription, and date of prescription fill. Injury severity scores (ISS) were calculated using ICDMAP-90 software (Johns Hopkins University, Baltimore, MD).
Case identification
We identified head-injured patients by encounters in the emergency room or admission to the hospital with an ICD-9 code indicating any injury at or above the brow line anteriorly and skull base posteriorly (concussion, skull fracture with or without ICH, and/or ICH alone; Appendix I). The presence of concomitant long bone fractures and torso injuries were also noted (Appendix II). A 2-month wash in period was allowed to measure exposure to drugs of interest.
Patients were considered warfarin users if they had 2 or more Part D claims (prescription fills) for warfarin/ Coumadin in the 60 days before their head injury encounter as long as those prescriptions were filled on different dates. Our definition of preinjury warfarin use ensures that our study patients were prescribed warfarin, which they took with enough regularity to refill it at least once in the immediate preinjury period. We also used Part D claims to identify the use of antiplatelet drugs (Appendix III) before injury using the same method used for warfarin use.
Outcomes of interest
Patients were considered to have sustained ICH as a result of head injury if one or more of their diagnosis codes included subdural, extradural, subarachnoid, and unspecified ICHs because of injury and/or cerebral lacerations and contusions (Appendix I). We first examined ICH incidence and need for hospitalization after head injury based on warfarin exposure. We then compared subsequent outcomes (need for ICU care, hospital LOS, ICU-LOS, 30-day in-hospital mortality) between warfarin users and nonusers who required hospitalization. In-hospital mortality was measured at 30 days based on the a priori assumption that deaths after more prolonged hospitalizations would be unlikely to be clinically attributable to warfarin use at the time of head injury.
Statistical analysis
Demographic (age, sex, race), clinical (Elixhauser comorbidity index), injury characteristics (concomitant long bone fracture, torso injury, ISS), and outcomes of warfarin users were compared with nonusers with univariate tests of association. Chi-square tests were used for categorical variables, Wilcoxon rank-sum tests for non-normally distributed continuous variables, and t tests for normally distributed continuous variables.
Multiple logistic regression analyses were used to examine the association of warfarin use with the occurrence of ICH and need for hospitalization in all head-injured patients while controlling for demographic, clinical, and presence of long bone fractures and/or torso injuries. Factors with univariate comparison (P % .2) or clinical importance were included in both models. The final model for odds of hospitalization also included ICH. Subgroup analyses were then performed to measure the independent effect of warfarin use on outcomes for patients hospitalized after head injury using a multiple logistic regression model for need for ICU care and a Cox proportional hazards model for 30-day in-hospital mortality. These analyses controlled for demographic and clinical factors considered in the hospital admission model described above. For the mortality model, the need for ICU care and ISS were also considered as covariates.
This study was deemed exempt by the University of Massachusetts Medical School institutional review board and was approved by the Center for Medicare and Medicaid Services via RESDAC. Analyses were performed using SAS 9.2 (SAS Institute, Cary NC, 2013).
Results
Of the 864,604 patients meeting eligibility criteria, 11,078 (1.3%) suffered head injury between March 2009 and December 2011 (Fig. 1) . Head-injured patients were mostly white (85%) women (69%) with greater than or equal to 3 Elixhauser comorbidities (53%), and a mean age of 80 (standard deviation 8.4) years. A majority of head-injured patients (n 5 9791, 88%) had isolated head injury with few having torso (n 5 664, 6.0%) or long bone (n 5 742, 6.7%) trauma. Five hundred seventy-two patients (5.2%) were exposed to warfarin before head trauma according to our criteria. Warfarin users were more likely to be female, older, and have higher Elixhauser and ISS scores than nonusers (Table 1) . Antiplatelet drug use at the time of head injury was also lower among patients using warfarin. Warfarin users had lower rates of concomitant torso trauma while rates of long bone fracture were similar across both groups.
Warfarin users were more likely to sustain ICH and to require hospitalization but had no difference in ICU utilization once hospitalized (Table 2) . Among those who were hospitalized and survived to discharge (or to 30 days), hospital LOS and ICU LOS were similar among warfarin users and nonusers. However, 30-day in-hospital mortality was nearly twice as high for warfarin users compared with nonusers (12% vs 6.8%, P , .01).
In multivariable analysis, preinjury warfarin use was an independent predictor of sustaining ICH after head injury (adjusted odds ratio [AOR] 1.4, 95% confidence interval [CI] 1.2 to 1.6) but was not a predictor of requiring hospitalization (AOR 1.2, 95% CI .99 to 1.5) (Fig. 2) . Age 75 to 84 (AOR 1.7, 95% CI 1.5 to 1.8), age greater than or equal to 85 (AOR 2.0, 95% CI 1.8 to 2.2), male sex (AOR 1.5, 95% CI 1.4 to 1.7), Asian race (AOR 1.5, 95% CI 1.2 to 1.9), Elixhauser index greater than or equal to 3 (AOR 1.2, 95% CI 1.1 to 1.3), concomitant torso injury (AOR 1.6, 95% CI 1.4 to 1.9), concomitant long bone fracture (AOR 1.3, 95% CI 1.1 to 1.5), and antiplatelet medication use (AOR 1.2, 95% CI 1.0 to 1.4) were also independent predictors of ICH. Similarly, age 75 to 84 (AOR 1.2, 95% CI 1.1 to 1.4), age greater than or equal to 85 (AOR 1.3, 95% CI 1.1 to 1.4), male sex (AOR 1.3, 95% CI 1.1 to 1.4), Elixhauser index greater than or equal to 3 (AOR 1.1, 95% CI 1.0 to 1.3), concomitant long bone fracture (AOR 3.2, 95% CI 2.6 to 4.0), concomitant torso trauma (AOR 5.8, 95% CI 4.4 to 7.5) and ICH (AOR 13, 95% CI 11 to 14) were all independent predictors of requiring hospitalization after head injury. Among those who survived to discharge or 30 days, whichever came sooner.
Among hospitalized patients (n 5 6,734), there was no difference in odds of requiring ICU care between warfarin users and nonusers (AOR 1.2, 95% CI .95 to 1.5). ICH conferred more than 3 times the odds of needing ICU care (AOR 3.5, 95% CI 3.1 to 4.0). Hispanic race (AOR 1.4, 95% CI 1.1 to 1.7) and the presence of torso injury (AOR 1.8, 95% CI 1.5 to 2.1) were also significant predictors of needing ICU care. Preinjury warfarin use doubled the risk of 30-day in-hospital mortality (AHR 2.0, 95% CI 1.5 to 2.6). Age greater than or equal to 85 years (AHR 1.3, 95% CI 1.0 to 1.7), ICH (AHR 2.2, 95% CI 1.5 to 3.4), and ISS per 1 unit (AHR 1.06, 95% CI 1.05 to 1.07) were also significant predictors of mortality. Elixhauser index and antiplatelet use were not independent predictors of in-hospital mortality.
Comments
This was a retrospective review of a national sample of Medicare beneficiaries evaluated for head injury. We used Part D prescription drug claims to more accurately identify preinjury warfarin use and determine the anticoagulant's effect on injury outcomes. Just over 1% of our national cohort was admitted for a head injury during our data period. If we were to extrapolate to the entire US Medicare population, an estimated 73,000 Medicare beneficiaries are expected to be admitted for head injury annually.
Overall, 5.2% of patients in our national sample were taking warfarin before sustaining head injury and warfarin use increased with age, from 3.2% in 65-to 75-year-olds to 6.2% in 85-to 104-year-olds. This is slightly lower than rates reported in other studies (7.3% to 19%) likely because of our strict criteria for identifying warfarin use. [5] [6] [7] [8] 10, 14 Based on anticipated aging of the US population and high prevalence of anticoagulation among elderly Americans, 1,2,15 our nation's healthcare system will be flooded with elderly patients who suffer head injury while anticoagulated in the near future. Thus, our finding that preinjury warfarin use among Medicare beneficiaries increased the risk of ICH and mortality after sustaining head injury, even after adjusting for potential confounders including injury severity and antiplatelet medication use, is concerning.
The risk of injury because of increasing frailty and decreasing cognition increases with age. 16 Once injured, elderly patients are at increased risk of poor outcomes after trauma, in particular after head injury. 17, 18 Meanwhile, warfarin is commonly prescribed for atrial fibrillation and other comorbidities, which are also more prevalent with advancing age. 19 While the current literature demonstrates a dramatic decrease in atrial fibrillation-related strokes 20, 21 and venous thromboembolism because of the use of anticoagulants, 22 studies regarding the safety of these medications have shown an increased risk of bleeding complications including ICH particularly for elderly patients. 23, 24 Importantly, many of these studies do not include traumatic ICH as an outcome, meaning that they could be overlooking serious effects of anticoagulation in the injury-prone elderly. As the process of aging progresses, the benefits of chronic anticoagulation may no longer outweigh the risks. Considering these risks is particularly important given the influx of newer anticoagulants that are being aggressively marketed to older American's with publically financed prescription drug coverage.
Our study indicates that warfarin use increases a patients' risk of incurring ICH in the setting of head injury by 40%. Antiplatelet use also conferred a slight increase in this risk of ICH, but the effect was less impressive. Our claims data did not contain exact mechanism of injury and physiologic markers of injury severity; thus, it was difficult to determine if the difference in the occurrence of ICH between the warfarin users and nonusers is attributable solely to warfarin exposure. However, even after adjusting for the presence of other injuries such as torso injuries and long bone fractures (which may serve as markers for polytrauma), the effect of warfarin on the odds of ICH remained significant. Thus, our findings support previous recommendations to automatically admit elderly patients on warfarin even in the face of normal examinations and imaging because of risk of potentially catastrophic, late-appearing head bleeds. 25, 26 We found that patients on warfarin at the time of injury had 2 times the risk of 30-day in-hospital mortality compared with those not on warfarin. Others have also reported increased mortality in anticoagulated trauma patients. [5] [6] [7] However, some have suggested that higher mortality in anticoagulated elderly trauma patients is attributable more to the effects of age and comorbidities than the effects of warfarin exposure. 10, 25 Studies comparing the effect of therapeutic and supratherapeutic International normalized ratio (INRs) to normal INRs have found worse head injury outcomes, including 5 times the odds of dying, among those with elevated INRs.
14 This would indicate that the driving force behind the elevated mortality risk in warfarin users is because of the anticoagulant effect itself rather than the presence of comorbidities that may be present in warfarin users. When we controlled for both age and comorbidities in our cohort, the effect of warfarin use on mortality after head injury remained significant.
There are several limitations to this study. As with all administrative data, we did not have access to some clinical information such as the exact mechanism of injury, laboratory values measuring the effectiveness of warfarin exposure, radiologic findings documenting exact severity of head injury, and methods, if any, for coagulopathy reversal. While we measured the effect of prescription antiplatelet agents on outcomes, Aspirin which is the most commonly used antiplatelet agent is available over the counter and are not reflected in Part D data.
Despite these important limitations to our knowledge, ours is one of the few national studies on the impact of warfarin on head injury outcomes. In comparison, previous research has largely been limited to locoregional studies that relied on reported use of warfarin at the time of presentation. 6, 8, 14, 25 Additionally, our use of prescription drug claims with a strict definition for warfarin exposure more accurately describes the impact of warfarin on head injury outcomes than other studies attempting to answer the same question using institutional databases and chart review.
We found that warfarin use at the time of head injury among Medicare beneficiaries aged greater than or equal to 65 years confers an increased risk of ICH and mortality even when accounting for age, comorbidities, injury severity, and prescription antiplatelet agents. As the US population continues to age and the anticoagulated elderly population continues to grow, physicians will need to carefully balance the benefits of anticoagulation with the risks of potentially catastrophic bleeding complications. 
